( MENAFN - PR Newswire) NEW YORK, Nov. 8, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Elanco Animal health Incorporated ("Elanco" or the "Company") (NYSE: ELAN ) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Elanco investors who were adversely affected by alleged securities fraud between November 7, 2023 and June 26, 2024.
Follow the LINK below to get more information and be contacted by a member of our team: ELAN investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.
CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) Zenrelia, a once-daily oral inhibitor for canine dermatology, was less safe than the Company had led investors to believe; (ii) Elanco was unlikely to meet its own previously issued timeline for the U.S. approval and commercial launch of both Zenrelia and Credelio Quattro, a broad spectrum parasiticide product for dogs; (iii) accordingly, the Company's business and/or financial prospects were overstated; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
WHAT'S NEXT? If you suffered a loss in Elanco during the relevant time frame, you have until December 6, 2024 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. NO.
